ArticleCancer medicine2020
Microsatellite instability and its associations with the clinicopathologic characteristics of diffuse large B-cell lymphoma.
Article in Cancer medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- Genomic loss of MLH1/PMS2 loci defines a mismatch repair deficient subgroup in monomorphic epitheliotropic intestinal T-cell lymphoma.Blood cancer journal · 2026Article
- Personalized Immunotherapy for T Cell Lymphomas: From Immune Escape to Precision Therapeutics.Journal of personalized medicine · 2025Review
- Mismatch Repair Deficiency and the Role of Non-Canonical Functions in Cancer: Diagnosis and Therapeutic Implications.International journal of molecular sciences · 2025Review
- Shared genomic features of HIV+ diffuse large B-cell lymphoma in two African cohorts.Scientific reports · 2025Article
- Molecular analysis of three DNA mismatch repair protein variants in Chinese families with suspected Lynch syndrome.Frontiers in medicine · 2025Article
- DNA mismatch repair defect and intratumor heterogeneous deficiency differently impact immune responses in diffuse large B-cell lymphoma.Oncoimmunology · 2024Article
- PD-L1Cold Spring Harbor molecular case studies · 2023Article
- Efficacy of Immune Checkpoint Blockade and Biomarkers of Response in Lymphoma: A Narrative Review.Biomedicines · 2023Review
- Resistance mechanisms of immune checkpoint inhibition in lymphoma: Focusing on the tumor microenvironment.Frontiers in pharmacology · 2023Review
- Article
- STR Profiling Reveals Tumor Genome Instability in Primary Mediastinal B-Cell Lymphoma.Current oncology (Toronto, Ont.) · 2022Article
- An unusual case of microsatellite instability-high/deficient mismatch repair (MSI-H/dMMR) diffuse large B-cell lymphoma revealed by targeted gene sequencing.Journal of pathology and translational medicine · 2022Article
- Article
- Microsatellite instability and its associations with the clinicopathologic characteristics of diffuse large B-cell lymphoma.Cancer medicine · 2020Article
- Predicting Responses to Checkpoint Inhibitors in Lymphoma: Are We Up to the Standards of Solid Tumors?Clinical Medicine Insights. Oncology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microsatellite instability (MSI) has been investigated as a prognostic and predictive factor for chemotherapy in colorectal cancer and has recently been demonstrated to be predictive of the PD-1/PD-L1 checkpoint blockade response in various solid tumors. However, MSI status in diffuse large B-cell lymphomas (DLBCLs) has not been thoroughly explored. This study investigated MSI status in DLBCLs and analyzed the associations between MSI and clinicopathologic characteristics and clinical outcomes. Ninety-two cases of primary DLBCLs treated with R-CHOP/CHOP chemotherapy between 2009 and 2017 were collected. MSI detection was performed by the Promega MSI Analysis System. The protein expression of MLH1, MSH2, MSH6, and PMS2 was detected by immunohistochemistry. The associations of MSI-H and MSI-L with progression-free survival (PFS) and overall survival (OS) were assessed by COX models and Kaplan-Meier curves. The correlations of complete response (CR) after R-CHOP/CHOP chemotherapy with MSI-H and MSI-L were examined by univariate and multivariate logistic regression analyses, respectively. 3 of 92 cases (3.2%) were high MSI (MSI-H), and 9 cases (9/92, 9.8%) exhibited low MSI (MSI-L). One case with MSI-H showed negative expression of MSH2 and MSH6. Univariate analysis indicated that MSI-L was correlated with poor response to R-CHOP/CHOP chemotherapy in DLBCLs (OR, 0.178; 95% CI, 0.041-0.776; P = .022). Multivariate analysis showed that MSI-L was an independent predictive factor for non-CR to R-CHOP/CHOP chemotherapy (OR, 0.144; 95% CI, 0.027-0.761; P = .023). Kaplan-Meier curves showed that there was a trend that MSI-H patients had favorable PFS (P = .36) and OS (P = .48), which did not have statistical significance and MSI-L was not significantly correlated with PFS (P = .24) and OS (P = .52).Our study indicated that there existed MSI-H and MSI-L in DLBCLs. MSI-L could be an independent predictive factor for the chemotherapy response in DLBCLs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.